Sharifi, N., Kayani, M., Murphy, L., Diaz, R., Grist, E., Kote-Jarai, Z., Eeles, R. A., Leone, G., Clarke, N. W., Parmar, M. K. B., Brown, L. C., James, N. D., Attard, G. (2025). HSD3B1 and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.234